Cn /En

News Center

——

Company news

Industry news

Introducing the latest features of InnoModels Biotechnology IC50 platform

Author:

InnoModels

Release time:

2024-09-05

In the field of biopharmaceutical research and development, cell activity assay is one of the key steps in evaluating drug efficacy and toxicity. InnoModels Biotechnology (Beijing) Co., Ltd. has made remarkable progress in the field of cell activity assay by virtue of its profound scientific background and advanced technology platform, especially its IC50 platform, which has become the focus of attention in the industry with its unique advantages. In this article, we will introduce the latest features of InnoModels Biotechnology IC50 platform in detail.
Abundant Cell Bank Resources
The InnoModels IC50 platform has more than 400 human-derived tumor cell lines, which cover a wide range of cancer types and subtypes. This rich cell bank resource provides researchers with a wide range of choices to find the most suitable cell models, whether for anticancer drug screening or mechanism research. Meanwhile, all cells are tested for STR (Short Tandem Repeat Sequence) before use to ensure the accuracy of cell identity and improve the reliability of experiments.
High-quality experimental services
The experimental team of the IC50 platform at InnoModels Biotechnology has more than 15 years of experience in IC50 assay and cell culture, and they have accumulated a wealth of knowledge and experience in the field of cell activity detection. The team members are able to provide professional services to ensure the accuracy and reliability of the experimental results. In addition, the platform strictly follows standardized experimental procedures to ensure that the results of each experiment are credible, thus providing customers with high-quality and reliable cell activity data.

Advanced Assay Technology
The InnoModels Biotechnology IC50 platform not only adopts the traditional CCK8 and MTT assays, but also introduces the XTT assay, an assay similar to the MTT assay, which assesses cell proliferation and activity by detecting enzyme activity within the cell. This method has the advantages of easy operation, high sensitivity and stable results, which can reflect the efficacy and toxicity of drugs more accurately.
Efficient Experimental Process
On the InnoModels IC50 platform, the experimental cycle can be significantly shortened, while the throughput of the tested drugs can be dramatically increased. This advantage is due to the high-throughput screening technology adopted by the platform, which is able to screen a large number of drugs in a short period of time, thus improving R&D efficiency. In addition, the platform is equipped with advanced experimental equipment and instruments, such as the Opera Phenix™ High-Inclusion Screening System, which further enhances the degree of automation and accuracy of the experiments.
Unique Modeling Platform
In addition to conventional cell activity assay services, InnoModels Biotechnology has unique model platforms including iHuPBMC-T, iHuPBMC-NK, second-generation PDX model platforms, and dual humanized model platforms. These modeling platforms can simultaneously rebuild multiple human immune cells including T cells and NK cells in mice while highly stable PDX models are rebuilt, thus realizing a full-flow in vitro to in vivo alternative model development pathway for immunotherapy. This feature gives InnoModels Biotechnology a unique advantage in the study of tumors and tumor immunotherapy.
Conclusion
With its rich cell bank resources, high-quality experimental services, advanced detection technologies, efficient experimental processes and unique model platform, the IC50 platform of InnoModels Biotechnology has demonstrated strong competitiveness and broad development prospects in the field of biopharmaceutical research and development. In the future, InnoModels Biotechnology will continue to provide more high-quality and efficient cell activity assay services to provide strong support for new drug R&D.

InnoModels Biotechnology ELISpot Platform

InnoModels Biotechnology PDC In Vitro High-Throughput Pharmacodynamic Evaluation Platform

InnoModels Biotechnology ELISpot Platform

InnoModels Biotechnology PDC In Vitro High-Throughput Pharmacodynamic Evaluation Platform

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License